Referred to the House Committee on Energy and Commerce.
This bill nullifies the Food and Drug Administration's January 2023 modifications to the risk evaluation and mitigation strategy (REMS) for the drug mifepristone. It also bars the Department of Health and Human Services and its component heads from establishing, implementing, or enforcing any REMS provision for mifepristone that is substantially similar to the nullified modifications.
Progressives emphasize access and depoliticizing FDA decisions.
Relative to its intended legislative type, this bill is a clear and narrowly focused substantive policy change that directly targets a specific set of FDA actions and constrains agency authority.
This bill nullifies the Food and Drug Administration's January 2023 modifications to the risk evaluation and mitigation strategy (REMS) for the drug mifepristone.
It also bars the Department of Health and Human Services and its component heads from establishing, implementing, or enforcing any REMS provision for mifepristone that is substantially similar to the nullified modifications.
Narrow but high‑salience abortion regulation likely to pass one chamber only under polarized conditions; overcoming Senate barriers and enactment is unlikely.
Relative to its intended legislative type, this bill is a clear and narrowly focused substantive policy change that directly targets a specific set of FDA actions and constrains agency authority. It succeeds in stating its core purpose and identifying the legal locus (REMS under 21 U.S.C. 355-1).
Progressives emphasize access and depoliticizing FDA decisions.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize access and depoliticizing FDA decisions.
Likely views the bill as an administrative reversal that restricts access to a medication used in reproductive healthcare and as politicizing FDA regulatory decisions.
Concern will focus on patient access, medical autonomy, and precedent of Congress overruling agency expertise.
Will weigh administrative authority, public health implications, and legal clarity.
Likely concerned about the vague "substantially similar" ban and potential for litigation, while assessing actual safety data behind the 2023 REMS modifications.
Likely views the bill favorably as reversing FDA actions perceived as loosening controls on mifepristone and as preventing future regulatory changes that would expand access.
Emphasizes patient safety and congressional oversight.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow but high‑salience abortion regulation likely to pass one chamber only under polarized conditions; overcoming Senate barriers and enactment is unlikely.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize access and depoliticizing FDA decisions.
Narrow but high‑salience abortion regulation likely to pass one chamber only under polarized conditions; overcoming Senate barriers and ena…
Relative to its intended legislative type, this bill is a clear and narrowly focused substantive policy change that directly targets a specific set of FDA actions and constrains agency authority. It succeeds in stating…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.